These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25798911)

  • 21. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.
    Kraus SR; Ruiz-Cerdá JL; Martire D; Wang JT; Wagg AS
    Urology; 2010 Dec; 76(6):1350-7. PubMed ID: 20974482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
    Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
    BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
    Wagg A; Khullar V; Michel MC; Oelke M; Darekar A; Bitoun CE
    Neurourol Urodyn; 2014 Jan; 33(1):106-14. PubMed ID: 23460503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
    Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
    Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.
    Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Guan Z; Choo MS
    Int J Clin Pract; 2009 Apr; 63(4):560-7. PubMed ID: 19348029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.
    Angulo JC; Valpas A; Rejas J; Linden K; Kvasz M; Snedecor SJ
    Clin Drug Investig; 2014 May; 34(5):297-307. PubMed ID: 24567280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
    Morris V; Wagg A
    Drug Des Devel Ther; 2014; 8():113-9. PubMed ID: 24470751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials.
    Wyndaele JJ; Schneider T; MacDiarmid S; Scholfield D; Arumi D
    Int J Clin Pract; 2014 Jul; 68(7):830-40. PubMed ID: 24754814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.
    Sand PK; Heesakkers J; Kraus SR; Carlsson M; Guan Z; Berriman S
    Drugs Aging; 2012 Feb; 29(2):119-31. PubMed ID: 22276958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.
    Cardozo L; Hall T; Ryan J; Ebel Bitoun C; Kausar I; Darekar A; Wagg A
    Int Urogynecol J; 2012 Nov; 23(11):1581-90. PubMed ID: 22576329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
    Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
    Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to fesoterodine in women with overactive bladder in routine clinical practice.
    Simó M; Porta O; Pubill J; Castillo MT; Mora I; Huguet E; Ortega JA; Martínez E
    Actas Urol Esp; 2015 May; 39(4):222-8. PubMed ID: 25442908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fesoterodine: Pharmacological properties and clinical implications.
    Gamé X; Peyronnet B; Cornu JN
    Eur J Pharmacol; 2018 Aug; 833():155-157. PubMed ID: 29803689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolterodine for the treatment of urge urinary incontinence.
    Elterman DS; Chughtai B; Kaplan SA; Barkin J
    Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.